Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China · Delayed Price · Currency is CNY 5.82
+0.09 (1.57%)
Apr 29, 2026, 3:04 PM CST
SHE:300039 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,035 | 1,153 | 1,471 | 1,591 | 1,117 | 1,099 |
Other Revenue | - | - | 1.9 | 3.03 | 2.25 | 1.29 |
| 1,035 | 1,153 | 1,473 | 1,594 | 1,119 | 1,101 | |
Revenue Growth (YoY) | -25.97% | -21.76% | -7.57% | 42.47% | 1.66% | 21.21% |
Cost of Revenue | 204.06 | 222.04 | 272.96 | 311.82 | 247.85 | 234.1 |
Gross Profit | 831.22 | 930.62 | 1,200 | 1,282 | 871 | 866.48 |
Selling, General & Admin | 498.96 | 562.71 | 727.1 | 858.13 | 612.86 | 652.66 |
Research & Development | 79.68 | 88.27 | 99.79 | 95.87 | 52.97 | 79.32 |
Other Operating Expenses | 6.81 | 7.2 | 22.76 | 23.92 | 16.92 | 11.5 |
Operating Expenses | 585.44 | 658.19 | 845.49 | 972.48 | 689.51 | 747.13 |
Operating Income | 245.78 | 272.44 | 354.87 | 309.75 | 181.49 | 119.35 |
Interest Expense | - | - | -0.04 | - | - | -0.15 |
Interest & Investment Income | 16.78 | 20.41 | 64.5 | 60.87 | 42.66 | 44.77 |
Other Non Operating Income (Expenses) | 41.88 | 39.57 | 0.04 | -0.57 | -0.16 | -0.03 |
EBT Excluding Unusual Items | 304.43 | 332.41 | 419.37 | 370.05 | 224 | 163.94 |
Impairment of Goodwill | - | - | - | -9.04 | -4.75 | -4.71 |
Gain (Loss) on Sale of Investments | -8.49 | -10.23 | 1.1 | -4.54 | -6.59 | 1.8 |
Gain (Loss) on Sale of Assets | 0.03 | 0.04 | -0.26 | -0.21 | -0.17 | -0.22 |
Asset Writedown | -0.17 | -0.17 | -0.62 | -0.1 | - | - |
Other Unusual Items | - | - | 14.59 | 27.38 | 13.71 | 8.84 |
Pretax Income | 295.8 | 322.05 | 434.18 | 383.53 | 226.19 | 169.65 |
Income Tax Expense | 37.19 | 44.05 | 59.27 | 56.63 | 36.11 | 29.54 |
Earnings From Continuing Operations | 258.61 | 278 | 374.91 | 326.9 | 190.08 | 140.11 |
Minority Interest in Earnings | 0.54 | 0.58 | 0.67 | 0.97 | 0.72 | 0 |
Net Income | 259.16 | 278.58 | 375.58 | 327.87 | 190.8 | 140.11 |
Net Income to Common | 259.16 | 278.58 | 375.58 | 327.87 | 190.8 | 140.11 |
Net Income Growth | -30.22% | -25.82% | 14.55% | 71.84% | 36.18% | 32.03% |
Shares Outstanding (Basic) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Shares Outstanding (Diluted) | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 | 1,046 |
Shares Change (YoY) | 0.03% | 0.02% | 0.00% | -0.02% | 0.01% | 0.04% |
EPS (Basic) | 0.25 | 0.27 | 0.36 | 0.31 | 0.18 | 0.13 |
EPS (Diluted) | 0.25 | 0.27 | 0.36 | 0.31 | 0.18 | 0.13 |
EPS Growth | -30.24% | -25.84% | 14.54% | 71.88% | 36.17% | 31.97% |
Free Cash Flow | 166.25 | 203.7 | 138.43 | 353.59 | 344.8 | 83.53 |
Free Cash Flow Per Share | 0.16 | 0.20 | 0.13 | 0.34 | 0.33 | 0.08 |
Dividend Per Share | - | - | 0.100 | 0.100 | 0.060 | 0.050 |
Dividend Growth | - | - | - | 66.67% | 20.00% | 66.67% |
Gross Margin | 80.29% | 80.74% | 81.47% | 80.44% | 77.85% | 78.73% |
Operating Margin | 23.74% | 23.64% | 24.09% | 19.43% | 16.22% | 10.84% |
Profit Margin | 25.03% | 24.17% | 25.49% | 20.57% | 17.05% | 12.73% |
Free Cash Flow Margin | 16.06% | 17.67% | 9.40% | 22.18% | 30.82% | 7.59% |
EBITDA | 280.7 | 307.46 | 390.29 | 347.28 | 213.2 | 153.21 |
EBITDA Margin | 27.11% | 26.67% | 26.49% | 21.79% | 19.05% | 13.92% |
D&A For EBITDA | 34.92 | 35.02 | 35.42 | 37.53 | 31.71 | 33.86 |
EBIT | 245.78 | 272.44 | 354.87 | 309.75 | 181.49 | 119.35 |
EBIT Margin | 23.74% | 23.64% | 24.09% | 19.43% | 16.22% | 10.84% |
Effective Tax Rate | 12.57% | 13.68% | 13.65% | 14.77% | 15.96% | 17.41% |
Revenue as Reported | - | - | 1,473 | 1,594 | 1,119 | 1,101 |
Advertising Expenses | - | - | - | - | - | 11.24 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.